A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance…
If I stop phenibut suddenly, published cases show people needing intensive care — can we plan a supervised taper rather than my stopping on my own?
Suggestive but preliminary. Not settled. how we score evidence
Caveat on this rating: The authors state plainly that the whole data set is case reports and is therefore subject to publication bias, that reported doses may not reflect what unregulated products actually contained, and that people describing single-substance use may have been using other drugs too.
Phenibut has never been approved by the FDA for any medical use in the United States and is not a lawful dietary supplement ingredient: the FDA has stated that phenibut does not meet the statutory definition of a dietary ingredient, that products listing it as one are misbranded, and it issued
A PRISMA systematic review screened 515 articles and found 25 usable published phenibut withdrawal cases — all case reports or conference abstracts, no controlled studies. The shortest use before withdrawal was one week at 2-3 g/day, the median daily dose was 10 g, withdrawal began as soon as two hours after the last dose, 64% worsened within 24 hours of reaching care, 24% were intubated, 44% went to the ICU, and 76% needed at least two drugs to control symptoms. Every abrupt-cessation case was admitted as an inpatient.
Worth asking
If I stop phenibut suddenly, published cases show people needing intensive care — can we plan a supervised taper rather than my stopping on my own?
Source
A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance versus polysubstance withdrawal. — Feldman R, Autry B, Dukes J, Lofy T, Marchetti G, Patt A, Batterman N, Theobald J. (2023)
Reputable peer-reviewed journal
Read the source: https://doi.org/10.1080/15563650.2023.2285702
DOI: 10.1080/15563650.2023.2285702
How this was scored
- Study design
- Systematic review of observational studies
- Funding
- Funding not disclosed
- Published in
- Reputable peer-reviewed journal
- Sample size
- 25
- Preregistered
- No
- Conflicts disclosed
- No
- Independent of proponent
- Yes
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published August 19, 2026.
Where we put this study in context
Questions
How strong is the evidence behind this?
Resolv rates this source "early signal". Suggestive but preliminary. Not settled. It scores 54 out of 100 on our published rubric. One caveat travels with that badge: The authors state plainly that the whole data set is case reports and is therefore subject to publication bias, that reported doses may not reflect what unregulated products actually contained, and that people describing single-substance use may have been using other drugs too. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance versus polysubstance withdrawal. — Feldman R, Autry B, Dukes J, Lofy T, Marchetti G, Patt A, Batterman N, Theobald J. (2023). Published in: Reputable peer-reviewed journal. DOI: 10.1080/15563650.2023.2285702. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Systematic review of observational studies. Funding: Funding not disclosed. The researchers were independent of whoever benefits from the result. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is phenibut, noofen, anvifen, fenibut, beta-phenyl-gaba, 4-amino-3-phenylbutyric acid, phenygam FDA approved for this use?
No. Its current status is: Not FDA-evaluated for this use. Phenibut has never been approved by the FDA for any medical use in the United States and is not a lawful dietary supplement ingredient: the FDA has stated that phenibut does not meet the statutory definition of a dietary ingredient, that products listing it as one are misbranded, and it issued
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.